Biogen Idec Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

220.22USD
4:00pm EDT
Price Change (% chg)

$2.09 (+0.96%)
Prev Close
$218.13
Open
$218.82
Day's High
$221.53
Day's Low
$218.03
Volume
365,053
Avg. Vol
465,996
52-wk High
$242.52
52-wk Low
$134.00

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company... (more)

Overall

Beta: 0.90
Market Cap (Mil.): $51,843.30
Shares Outstanding (Mil.): 237.67
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 32.34 47.13 37.76
EPS (TTM): 6.74 -- --
ROI: 18.74 -2.58 18.76
ROE: 22.70 -2.66 19.59
Search Stocks

Biogen's new MS drug shines in market debut

- Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera had surpassed Wall Street's most bullish forecasts, raising expectations that it will eventually become the dominant oral MS treatment.

25 Jul 2013

UPDATE 3-Biogen's new MS drug shines in market debut

July 25 - Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera had surpassed Wall Street's most bullish forecasts, raising expectations that it will eventually become the dominant oral MS treatment.

25 Jul 2013

Biogen new MS drug sales shine in first quarter on market

July 25 - Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera that blew away initial Wall Street estimates, confirming an extremely strong launch for a medicine expected to dominate the market for oral treatments.

25 Jul 2013

Biogen investigates death of patient who took MS drug Tecfidera

July 22 - Biogen Idec Inc is investigating the death of a patient who had taken its new multiple sclerosis drug, Tecfidera, the company said on Monday.

22 Jul 2013

Divisive Elan boss Martin faces ownership showdown

DUBLIN/NEW YORK - When Kelly Martin, a former Merrill Lynch banker with no drug industry experience, took over as CEO of Ireland's Elan in 2003, analysts assumed his mandate was to clean up the troubled company and sell it.

13 Jun 2013

Biogen delays MS drug's EU launch to secure market exclusivity

May 30 - Biogen Idec Inc expects a delay in the European launch of its multiple sclerosis drug Tecfidera as the drugmaker works to secure exclusive data that could potentially protect its treatment from generic competition for a longer period.

30 May 2013

Biogen profit beats estimates, raises 2013 forecast

- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.

25 Apr 2013

UPDATE 3-Biogen profit beats estimates, raises 2013 forecast

April 25 - Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.

25 Apr 2013

BRIEF-Biogen sees Tecfidera becoming leading oral drug MS drug

April 25 - Biogen Idec Inc : * Says believes tecfidera will become leading oral drug in ms market

25 Apr 2013

Biogen profit beats estimates, raises 2013 forecast

- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecast.

25 Apr 2013

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF66.60 +0.35
Teva Pharmaceutical Industries Limited (TEVA.TA) 13,920.00₪ -200.00
Sanofi SA (SASY.PA) €76.85 -3.32
Pfizer Inc. (PFE.N) $29.11 -0.12
Genmab A/S (GEN.CO) kr.161.40 -0.60
GlaxoSmithKline plc (GSK.L) 1,712.50p +28.50
Johnson & Johnson (JNJ.N) $93.77 +0.27
Abbott Laboratories (ABT.N) $36.84 +0.21
Amgen, Inc. (AMGN.OQ) $109.45 +1.16
UCB SA (UCB.BR) €44.24 +0.91

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Wright Reports
$495.00
Provider: Stock Traders Daily
$495.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks